1
|
Berry JL, Brooks-Russell A, Beuning CN, Limbacher SA, Lovestead TM, Jeerage KM. Cannabinoids detected in exhaled breath condensate after cannabis use. J Breath Res 2024; 18:041002. [PMID: 39008974 PMCID: PMC11264354 DOI: 10.1088/1752-7163/ad6347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Accepted: 07/15/2024] [Indexed: 07/17/2024]
Abstract
Cannabinoids can be detected in breath after cannabis use, but different breath matrices need to be explored as studies to date with filter-based devices that collect breath aerosols have not demonstrated that breath-based measurements can reliably identify recent cannabis use. Exhaled breath condensate (EBC) is an unexplored aqueous breath matrix that contains condensed volatile compounds and water vapor in addition to aerosols. EBC was collected from participants both before and at two time points (0.7 ± 0.2 h and 1.7 ± 0.3 h) after observed cannabis use. Eleven different cannabinoids were monitored with liquid chromatography tandem mass spectrometry. Five different cannabinoids, including Δ9-tetrahydrocannabinol (THC), were detected in EBC collected from cannabis users. THC was detected in some EBC samples before cannabis use, despite the requested abstinence period. THC was detected in all EBC samples collected at 0.7 h post use and decreased for all participants at 1.7 h. Non-THC cannabinoids were only detected after cannabis use. THC concentrations in EBC samples collected at 0.7 h showed no trend with sample metrics like mass or number of breaths. EBC sampling devices deserve further investigation with respect to modes of cannabis use (e.g, edibles), post use time points, and optimization of cannabinoid recovery.
Collapse
Affiliation(s)
- Jennifer L Berry
- Applied Chemical and Materials Division, National Institute of Standards and Technology, 325 Broadway, Boulder, CO, United States of America
| | - Ashley Brooks-Russell
- Colorado School of Public Health, University of Colorado Anschutz Medical, 13001 E. 17th Place, Aurora, CO, United States of America
| | - Cheryle N Beuning
- Applied Chemical and Materials Division, National Institute of Standards and Technology, 325 Broadway, Boulder, CO, United States of America
| | - Sarah A Limbacher
- Colorado School of Public Health, University of Colorado Anschutz Medical, 13001 E. 17th Place, Aurora, CO, United States of America
| | - Tara M Lovestead
- Applied Chemical and Materials Division, National Institute of Standards and Technology, 325 Broadway, Boulder, CO, United States of America
| | - Kavita M Jeerage
- Applied Chemical and Materials Division, National Institute of Standards and Technology, 325 Broadway, Boulder, CO, United States of America
| |
Collapse
|
2
|
Melén CM, Merrien M, Wasik AM, Sander B, Wahlin BE, Panagiotis G, Beck O. Δ 9-THC and CBD in Plasma, Oral Fluid, Exhaled Breath, and Urine from 23 Patients Administered Sativex. Cannabis Cannabinoid Res 2024; 9:e839-e846. [PMID: 37083482 DOI: 10.1089/can.2022.0179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/22/2023] Open
Abstract
Background: Detecting the presence of Δ9-THC and CBD is mainly done through venous blood sampling, but other methods are becoming available. Oromucosal administration of Δ9-THC and CBD is less studied than inhalation, but this mode of administration is growing. In this study, we analyze samples obtained through invasive and noninvasive methods in a cohort of patients given oromucosally administered Δ9-THC and CBD to gain understanding in the strengths and weaknesses of the various detection methods. Materials and Methods: Blood, oral fluid (OF), exhaled breath, and urine were collected at several time points from 23 cannabis-naive patients after receiving a single dose of Sativex®; dose ranges: Δ9-THC, 2.7-18.9 mg; CBD 2.5-17.5 mg. Detection of Δ9-THC and CBD was done using liquid chromatography-mass spectrometry methods. Results: Δ9-THC and CBD were present in plasma, OF, and exhaled breath in all 23 patients. The detection time of Δ9-THC and CBD in OF and exhaled breath was longer than in blood. Urine analysis detected the Δ9-THC carboxy metabolite (THC-COOH) up to 7 days after administration, also in a patient who received 8.1/7.5 mg Δ9-THC/CBD. Conclusion: Time to detection of cannabinoids in blood samples was shorter than in exhaled breath and OF. Relative ease of sample collection combined with high sensitivity makes OF and exhaled breath specimens a valuable addition when samples are handled correctly. Δ9-THC metabolites were detected for an unexpected long period of time in urine. EudraCT Number: 2014-005553-39. Date of registration, December 29, 2015.
Collapse
Affiliation(s)
- Christopher M Melén
- Unit of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| | - Magali Merrien
- Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Agata M Wasik
- Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Birgitta Sander
- Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
| | - Björn Engelbrekt Wahlin
- Unit of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
| | - Georgios Panagiotis
- Department of Clinical Pharmacology, University Hospital, Stockholm, Sweden
- Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Olof Beck
- Department of Clinical Pharmacology, University Hospital, Stockholm, Sweden
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Sinapour H, Guterstam J, Grosse S, Astorga-Wells J, Stambeck P, Stambeck M, Winberg J, Hermansson S, Beck O. Validation and application of an automated multitarget LC-MS/MS method for drugs of abuse testing using exhaled breath as specimen. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1240:124142. [PMID: 38718698 DOI: 10.1016/j.jchromb.2024.124142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Revised: 04/26/2024] [Accepted: 04/27/2024] [Indexed: 06/03/2024]
Abstract
Aerosol microparticles in exhaled breath carry non-volatile compounds from the deeper parts of the lung. When captured and analyzed, these aerosol microparticles constitute a non-invasive and readily available specimen for drugs of abuse testing. The present study aimed to evaluate a simple breath collection device in a clinical setting. The device divides a breath sample into three parallel "collectors" that can be individually analyzed. Urine was used as the reference specimen, and parallel specimens were collected from 99 patients undergoing methadone maintenance treatment. Methadone was used as the primary validation parameter. A sensitive multi-analyte method using tandem liquid chromatography - mass spectrometry was developed and validated as part of the project. The method was successfully validated for 36 analytes with a limit of detection of 1 pg/collector for most compounds. Based on the validation results tetrahydrocannabinol THC), cannabidiol (CBD), and lysergic acid diethylamide (LSD) are suitable for qualitative analysis, but all other analytes can be quantitively assessed by the method. Methadone was positive in urine in 97 cases and detected in exhaled breath in 98 cases. Median methadone concentration was 64 pg/collector. The methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) was detected in 90 % of the cases but below 10 pg/collector in most. Amphetamine was also present in the urine in 17 cases and in exhaled breath in 16 cases. Several other substances were detected in the exhaled breath and urine samples, but at a lower frequency. This study concluded that the device provides a specimen from exhaled breath, that is useful for drugs of abuse testing. The results show that high analytical sensitivity is needed to achieve good detectability and detection time after intake.
Collapse
Affiliation(s)
| | - Joar Guterstam
- Karolinska Institute, Department of Clinical Neuroscience, Stockholm, Sweden
| | - Susan Grosse
- Workplace Drugs Testing Laboratory, Eurofins Forensic Services, London, UK
| | | | - Peter Stambeck
- Workplace Drugs Testing Laboratory, Eurofins Forensic Services, London, UK
| | | | | | | | - Olof Beck
- Karolinska Institute, Department of Clinical Neuroscience, Stockholm, Sweden.
| |
Collapse
|
4
|
DeGregorio MW, Kao CJ, Wurz GT. Complexity of Translating Analytics to Recent Cannabis Use and Impairment. J AOAC Int 2024; 107:493-505. [PMID: 38410076 DOI: 10.1093/jaoacint/qsae015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 01/31/2024] [Accepted: 02/21/2024] [Indexed: 02/28/2024]
Abstract
While current analytical methodologies can readily identify cannabis use, definitively establishing recent use within the impairment window has proven to be far more complex, requiring a new approach. Recent studies have shown no direct relationship between impairment and Δ9-tetra-hydrocannabinol (Δ9-THC) concentrations in blood or saliva, making legal "per se" Δ9-THC limits scientifically unjustified. Current methods that focus on Δ9-THC and/or metabolite concentrations in blood, saliva, urine, or exhaled breath can lead to false-positive results for recent use due to the persistence of Δ9-THC well outside of the typical 3-4 h window of potential impairment following cannabis inhalation. There is also the issue of impairment due to other intoxicating substances-just because a subject exhibits signs of impairment and cannabis use is detected does not rule out the involvement of other drugs. Compounding the matter is the increasing popularity of hemp-derived cannabidiol (CBD) products following passage of the 2018 Farm Bill, which legalized industrial hemp in the United States. Many of these products contain varying levels of Δ9-THC, which can lead to false-positive tests for cannabis use. Furthermore, hemp-derived CBD is used to synthesize Δ8-THC, which possesses psychoactive properties similar to Δ9-THC and is surrounded by legal controversy. For accuracy, analytical methods must be able to distinguish the various THC isomers, which have identical masses and exhibit immunological cross-reactivity. A new testing approach has been developed based on exhaled breath and blood sampling that incorporates kinetic changes and the presence of key cannabinoids to detect recent cannabis use within the impairment window without the false-positive results seen with other methods. The complexity of determining recent cannabis use that may lead to impairment demands such a comprehensive method so that irresponsible users can be accurately detected without falsely accusing responsible users who may unjustly suffer harsh, life-changing consequences.
Collapse
Affiliation(s)
- Michael W DeGregorio
- RCU Labs, Inc., 408 Sunrise Ave, Roseville, CA 95661-4123, United States
- Professor Emeritus, University of California, Davis, One Shields Avenue, Davis, CA 95616, United States
| | - Chiao-Jung Kao
- RCU Labs, Inc., 408 Sunrise Ave, Roseville, CA 95661-4123, United States
| | - Gregory T Wurz
- RCU Labs, Inc., 408 Sunrise Ave, Roseville, CA 95661-4123, United States
| |
Collapse
|
5
|
Salthammer T. The legalization of cannabis may result in increased indoor exposure to Δ 9-tetrahydrocannabinol. JOURNAL OF HAZARDOUS MATERIALS 2024; 464:132949. [PMID: 37976847 DOI: 10.1016/j.jhazmat.2023.132949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 10/28/2023] [Accepted: 11/05/2023] [Indexed: 11/19/2023]
Abstract
Cannabis is a genus of plants in the Cannabaceae family that contains tetrahydrocannabinolic acid. When heated or burned, the acid decarboxylates to form tetrahydrocannabinol (THC). Its (-)-trans-Δ9-THC isomer is a psychoactive substance that has been used as a drug for centuries. In most countries, both the private sale of cannabis products and their use for non-medical purposes are still prohibited by law. However, for some time now there has been societal and political pressure to at least partially legalize cannabis products. It can be expected that such a measure will lead to a significant increase in the consumption of cannabis. However, this also increases the possibility of involuntary passive exposure to THC and contamination of the indoor environment. In indoor sciences, THC is still a largely unknown or underrepresented substance. In this perspective paper, THC will therefore first be presented on the basis of its physical properties. Then, the distribution of THC in different indoor compartments and potential routes of passive exposure are discussed. Finally, an assessment of the future importance of THC for indoor use is made. Previous experience has shown that early monitoring is always advantageous so that preventive and protective measures can be taken quickly if necessary.
Collapse
Affiliation(s)
- Tunga Salthammer
- Department of Material Analysis and Indoor Chemistry, Fraunhofer WKI, 38108 Braunschweig, Germany.
| |
Collapse
|
6
|
Zhang J, Zhang Y, Xu C, Huang Z, Hu B. Detection of abused drugs in human exhaled breath using mass spectrometry: A review. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2023; 37 Suppl 1:e9503. [PMID: 36914281 DOI: 10.1002/rcm.9503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 02/07/2023] [Accepted: 03/08/2023] [Indexed: 06/18/2023]
Abstract
RATIONALE Human breath analysis has been attracting increasing interest in the detection of abused drugs in forensic and clinical applications because of its noninvasive sampling and distinctive molecular information. Mass spectrometry (MS)-based approaches have been proven to be powerful tools for accurately analyzing exhaled abused drugs. The major advantages of MS-based approaches include high sensitivity, high specificity, and versatile couplings with various breath sampling methods. METHODS Recent advances in the methodological development of MS analysis of exhaled abused drugs are discussed. Breath collection and sample pretreatment methods for MS analysis are also introduced. RESULTS Recent advances in technical aspects of breath sampling methods are summarized, highlighting active and passive sampling. MS methods for detecting different exhaled abused drugs are reviewed, emphasizing their features, advantages, and limitations. The future trends and challenges in MS-based breath analysis of exhaled abused drugs are also discussed. CONCLUSIONS The coupling of breath sampling methods with MS approaches has been proven to be a powerful tool for the detection of exhaled abused drugs, offering highly attractive results in forensic investigations. MS-based detection of exhaled abused drugs in exhaled breath is a relatively new field and is still in the early stages of methodological development. New MS technologies promise a substantial benefit for future forensic analysis.
Collapse
Affiliation(s)
- Jianfeng Zhang
- Institute of Mass Spectrometry and Atmospheric Environment, Guangdong Provincial Engineering Research Center for On-line Source Apportionment System of Air Pollution, Jinan University, Guangzhou, China
| | - Ying Zhang
- Key Laboratory of Forensic Toxicology (Ministry of Public Security), Beijing Municipal Public Security Bureau, Beijing, China
| | - Chunhua Xu
- Guangzhou Hexin Instrument Co., Ltd, Guangzhou, China
| | - Zhengxu Huang
- Institute of Mass Spectrometry and Atmospheric Environment, Guangdong Provincial Engineering Research Center for On-line Source Apportionment System of Air Pollution, Jinan University, Guangzhou, China
| | - Bin Hu
- Institute of Mass Spectrometry and Atmospheric Environment, Guangdong Provincial Engineering Research Center for On-line Source Apportionment System of Air Pollution, Jinan University, Guangzhou, China
| |
Collapse
|
7
|
Feltmann K, Elgán TH, Böttcher M, Lierheimer S, Hermansson S, Beck O, Gripenberg J. Feasibility of using breath sampling of non-volatiles to estimate the prevalence of illicit drug use among nightlife attendees. Sci Rep 2022; 12:20283. [PMID: 36434044 PMCID: PMC9700783 DOI: 10.1038/s41598-022-24741-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 11/18/2022] [Indexed: 11/27/2022] Open
Abstract
The prevalence of drug use among nightlife attendees needs to be accurately estimated to, for example, evaluate preventive interventions. This study tested the feasibility of using a breath-sampling device to estimate the prevalence of drug use among nightlife attendees. The study was conducted at five nightclubs and a large music festival in Stockholm, Sweden. Participants were invited to participate and microparticles in exhaled breath were sampled and analyzed for 47 compounds using a state-of-the-art analytic method that follows forensic standards. In addition, participants' breath alcohol concentration was measured and they were interviewed about demographics, drinking habits, and drug use. Of the people invited, 73.7% (n = 1223) agreed to participate, and breath samples were collected from 1204 participants. Breath sampling was fast and well-accepted by participants. 13 percent of participants tested positive for an illicit drug, but only 4.3% self-reported drug use during the last 48 h. The most common substances detected were cocaine, amphetamine, and MDMA. There was no agreement between self-reported and measured use of any drug. Breath sampling is a convenient method to test illicit drug use among a large number of participants at events, and can be used as an estimate of drug use prevalence.
Collapse
Affiliation(s)
- Kristin Feltmann
- STAD, Stockholm Prevents Alcohol and Drug Problems, Stockholm, Sweden ,grid.4714.60000 0004 1937 0626Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, plan 7, 11364 Stockholm, Sweden
| | - Tobias H. Elgán
- STAD, Stockholm Prevents Alcohol and Drug Problems, Stockholm, Sweden ,grid.4714.60000 0004 1937 0626Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, plan 7, 11364 Stockholm, Sweden
| | - Michael Böttcher
- MVZ Medizinische Labore Dessau Kassel GmbH, Dessau-Roßlau, Germany
| | | | | | - Olof Beck
- grid.4714.60000 0004 1937 0626Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, plan 7, 11364 Stockholm, Sweden
| | - Johanna Gripenberg
- STAD, Stockholm Prevents Alcohol and Drug Problems, Stockholm, Sweden ,grid.4714.60000 0004 1937 0626Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, plan 7, 11364 Stockholm, Sweden
| |
Collapse
|
8
|
Xu F, Zhou J, Yang H, Chen L, Zhong J, Peng Y, Wu K, Wang Y, Fan H, Yang X, Zhao Y. Recent advances in exhaled breath sample preparation technologies for drug of abuse detection. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2022.116828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
9
|
Puiu M, Bala C. Affinity Assays for Cannabinoids Detection: Are They Amenable to On-Site Screening? BIOSENSORS 2022; 12:608. [PMID: 36005003 PMCID: PMC9405638 DOI: 10.3390/bios12080608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 07/27/2022] [Accepted: 08/04/2022] [Indexed: 12/02/2022]
Abstract
Roadside testing of illicit drugs such as tetrahydrocannabinol (THC) requires simple, rapid, and cost-effective methods. The need for non-invasive detection tools has led to the development of selective and sensitive platforms, able to detect phyto- and synthetic cannabinoids by means of their main metabolites in breath, saliva, and urine samples. One may estimate the time passed from drug exposure and the frequency of use by corroborating the detection results with pharmacokinetic data. In this review, we report on the current detection methods of cannabinoids in biofluids. Fluorescent, electrochemical, colorimetric, and magnetoresistive biosensors will be briefly overviewed, putting emphasis on the affinity formats amenable to on-site screening, with possible applications in roadside testing and anti-doping control.
Collapse
Affiliation(s)
- Mihaela Puiu
- R&D Center LaborQ, University of Bucharest, 4-12 Regina Elisabeta Blvd., 030018 Bucharest, Romania
| | - Camelia Bala
- R&D Center LaborQ, University of Bucharest, 4-12 Regina Elisabeta Blvd., 030018 Bucharest, Romania
- Department of Analytical Chemistry, University of Bucharest, 4-12 Regina Elisabeta Blvd., 030018 Bucharest, Romania
| |
Collapse
|
10
|
Garzinsky AM, Thomas A, Thevis M. Probing for factors influencing exhaled breath drug testing in sports- Pilot studies focusing on the tested individual's tobacco smoking habit and sex. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2022; 36:e9262. [PMID: 35094434 DOI: 10.1002/rcm.9262] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/25/2022] [Accepted: 01/26/2022] [Indexed: 06/14/2023]
Abstract
RATIONALE Exhaled breath (EB) was found to be a promising matrix in the field of sports drug testing due to the non-invasive and non-intrusive sampling procedure, but significant inter-individual variations regarding detected drug concentrations have been observed in previous studies. To investigate whether the detectability of doping agents in EB is affected by sex or tobacco smoking, two administration studies were conducted with male and female smokers and nonsmokers concerning the elimination of the beta blocker propranolol and the stimulant pseudoephedrine into EB. METHODS Following the administration of 40 mg propranolol or 30 mg pseudoephedrine, a total of 19 participants, including female and male nonsmokers as well as female and male smokers, collected EB and dried blood spot (DBS) samples over a period of 24 h. Respective analyte concentrations were determined using liquid chromatography and high-resolution tandem mass spectrometry, and semi-quantitative assays were characterized with regard to selectivity, limit of detection and identification, precision, linearity, and carryover. RESULTS Both propranolol and pseudoephedrine were identified in post-administration EB samples from female and male nonsmokers as well as female and male smokers, and the maximum detected drug levels ranged from 9 to 2847 pg/cartridge for propranolol and from 26 to 4805 pg/cartridge for pseudoephedrine. The corresponding DBS levels were in a range of 4-30 ng/mL for propranolol and 55-186 ng/mL for pseudoephedrine. CONCLUSIONS Neither the consumption of cigarettes nor the sex appears to represent a decisive criterion as to the detectability of propranolol or pseudoephedrine in EB, but inter-individual variations regarding the detected drug levels were observed among all studied population groups.
Collapse
Affiliation(s)
- Ann-Marie Garzinsky
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, Germany
| | - Andreas Thomas
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, Germany
- European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany
| |
Collapse
|
11
|
A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window. Sci Rep 2021; 11:22776. [PMID: 34815467 PMCID: PMC8611040 DOI: 10.1038/s41598-021-02137-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 11/10/2021] [Indexed: 11/11/2022] Open
Abstract
Legalization of cannabis for medicinal and/or recreational use is expanding globally. Although cannabis is being regulated country by country, an accurate recent use test with indisputable results correlated with impairment has yet to be discovered. In the present study, a new approach for determining recent cannabis use within the impairment window after smoking was developed by studying 74 subjects with a mean age of 25 years and average use history of 9 years. Horizontal gaze nystagmus was evaluated along with subject self-assessments of impairment, and blood and breath samples were collected before and after smoking cannabis. Breath and blood pharmacokinetic parameters and cannabinoid profiles determined recent use within the impairment window. No subjects were positive for recent use pre-smoking, although all subjects had detectable cannabinoids in breath samples. We describe an inhaled cannabis recent use test that correlates with impairment and helps protect against wrongful prosecution and workplace discrimination.
Collapse
|
12
|
Analysis of cannabinoids in conventional and alternative biological matrices by liquid chromatography: Applications and challenges. J Chromatogr A 2021; 1651:462277. [PMID: 34091369 DOI: 10.1016/j.chroma.2021.462277] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 05/16/2021] [Accepted: 05/18/2021] [Indexed: 11/24/2022]
Abstract
Cannabis is by far the most widely abused illicit drug globe wide. The analysis of its main psychoactive components in conventional and non-conventional biological matrices has recently gained a great attention in forensic toxicology. Literature states that its abuse causes neurocognitive impairment in the domains of attention and memory, possible macrostructural brain alterations and abnormalities of neural functioning. This suggests the necessity for the development of a sensitive and a reliable analytical method for the detection and quantification of cannabinoids in human biological specimens. In this review, we focus on a number of analytical methods that have, so far, been developed and validated, with particular attention to the new "golden standard" method of forensic analysis, liquid chromatography mass spectrometry or tandem mass spectrometry. In addition, this review provides an overview of the effective and selective methods used for the extraction and isolation of cannabinoids from (i) conventional matrices, such as blood, urine and oral fluid and (ii) alternative biological matrices, such as hair, cerumen and meconium.
Collapse
|
13
|
Mooko T, Bala A, Tripathy S, Kumar CS, Mahadevappa CP, Chaudhary SK, Matsabisa MG. Cannabis Sativa L. Flower and Bud Extracts inhibited In vitro Cholinesterases and b-Secretase Enzymes Activities: Possible Mechanisms of Cannabis use in Alzheimer Disease. Endocr Metab Immune Disord Drug Targets 2021; 22:297-309. [PMID: 33618651 DOI: 10.2174/1871530321666210222124349] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 12/19/2020] [Accepted: 12/30/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND There are anecdotal claims on the use of Cannabis sativa L. in the treatment of Alzheimer's disease, but there is lack of scientific data to support the efficacy and safety of Cannabis sativa L. for Alzheimer's disease. AIM The aim of the study was to evaluate the effect of aerial parts of Cannabis sativa L. on the cholinesterases and β-secretase enzyme activity as one of the possible mechanisms of Alzheimer's disease. METHODS The phytochemical and heavy metal contents were analysed. The extracts were screened for acetylcholinesterase, butyrylcholinesterase and β-secretase activity. Cytotoxicity of extracts was performed in normal vero and pre-adipocytes cell lines. The extracts were characterized using high performance thin layer chromatography and high-performance liquid chromatography for their chemical fingerprints. Alkaloids, flavonoids and glycosides were present amongst the tested phytochemicals. Cannabidiol concentrations were comparatively high in the hexane and dichloromethane than in dichloromethane: methanol (1:1) and methanol extracts. RESULTS Hexane and dichloromethane extracts showed a better inhibitory potential towards cholinesterase activity, while water, hexane, dichloromethane: methanol (1:1) and methanol showed an inhibitory potential towards β-secretase enzyme activity. All extracts showed no cytotoxic effect on pre-adipocytes and vero cells after 24- and 48-hours of exposure. CONCLUSION Therefore, this may explain the mechanism through which AD symptoms may be treated and managed by Cannabis sativa L. extracts.
Collapse
Affiliation(s)
- Teboho Mooko
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Asis Bala
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Satyajit Tripathy
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Chethan S Kumar
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Chandrashekara P Mahadevappa
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Sushil K Chaudhary
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| | - Motlalepula G Matsabisa
- Department of Pharmacology, Indigenous Knowledge System Unit, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300. South Africa
| |
Collapse
|
14
|
Ramzy V, Priefer R. THC detection in the breath. Talanta 2021; 222:121528. [PMID: 33167238 DOI: 10.1016/j.talanta.2020.121528] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/05/2020] [Accepted: 08/06/2020] [Indexed: 01/13/2023]
Abstract
Cannabis legalization and common use has further driven the need for accurate THC detection and analysis for roadside testing. While reliable and accurate techniques, such as mass spectrometry (MS) exist for the analysis of THC, the market lacks technologies that are portable and can be utilized outside of a laboratory setting. Innovations utilizing unique technologies have steadily been increasing. These include carbon nanotubes, specifically semiconductor-enriched single-walled carbon nanotube (s-SWCNT) chemiresistors and carbon nanotubes with integrated molecularly imprinted polymers (MIPs), giant magnetoresistive (GMR) biosensors, capillary electrophoresis (CE) with ultraviolet light-emitting diode-induced native fluorescence (UV-LEDIF), and electrochemical detection with the use of screen printed carbon electrodes and N-(4-amino-3-methoxyphenyl)-methanesulfonamide. Finally, a novel device has been recently launched to detect THC in the breath with the use of TLC and fluorescent probes. This review highlights the technologies that have been, and are being, explored to ultimately lead to a portable road-side test for THC once further testing in practice has been completed.
Collapse
Affiliation(s)
- Veronika Ramzy
- Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, 02115, USA
| | - Ronny Priefer
- Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, 02115, USA.
| |
Collapse
|
15
|
Garzinsky AM, Thomas A, Krug O, Thevis M. Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2021; 35:e8939. [PMID: 32881194 DOI: 10.1002/rcm.8939] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 08/28/2020] [Indexed: 06/11/2023]
Abstract
RATIONALE Exhaled breath (EB) has been demonstrated to be a promising alternative matrix in sports drug testing due to its non-invasive and non-intrusive nature compared with urine and blood collection protocols. In this study, a pilot-test system was employed to create drug-containing aerosols simulating EB in support of the analytical characterization of EB sampling procedures, and the used analytical method was extended to include a broad spectrum of prohibited substances. METHODS Artificial and authentic EB samples were collected using sampling devices containing an electret filter, and doping agents were detected by means of liquid chromatography and tandem mass spectrometry with unispray ionization. The analytical approach was characterized with regard to specificity, limits of detection, carry-over, recovery and matrix effects, and the potential applicability to routine doping controls was shown using authentic EB samples collected after single oral dose applications of glucocorticoids and stimulants. RESULTS The analytical method was found to be specific for a total of 49 model substances relevant in sports drug testing, with detection limits ranging from 1 to 500 pg per cartridge. Both ion suppression (-62%) and ion enhancement (+301%) effects were observed, and all model compounds applied to EB sampling devices were still detected after 28 days of storage at room temperature. Authentic EB samples collected after the oral administration of 10 mg of prednisolone resulted in prednisolone findings in specimens obtained from 3 out of 6 participants up to 2 h. In octodrine, dimethylamylamine (DMAA) and isopropylnorsynephrine post-administration EB samples, the drugs were detected over a period of 50, 48, and 8 h, respectively. CONCLUSIONS With the analytical approach developed within this study, the identification of a broad spectrum of prohibited doping agents in EB samples was accomplished. Application studies and stability tests provided information to characterize EB as a potential matrix in sports drug testing.
Collapse
Affiliation(s)
- Ann-Marie Garzinsky
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, 50933, Germany
| | - Andreas Thomas
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, 50933, Germany
| | - Oliver Krug
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, 50933, Germany
- European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, 50933, Germany
- European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany
| |
Collapse
|
16
|
Ameline A, Raul JS, Kintz P. Characterization of Cannabidiol in Alternative Biological Specimens and Urine, After Consumption of an Oral Capsule. J Anal Toxicol 2020; 46:bkaa191. [PMID: 33330903 DOI: 10.1093/jat/bkaa191] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 11/20/2020] [Accepted: 12/04/2020] [Indexed: 11/12/2022] Open
Abstract
Among the hundred cannabinoids present in cannabis sativa indica, cannabidiol is a phytocannabinoid discovered in 1940, which can account for up to 40 % of the plant's extract. Medically, it has been proposed to treat convulsions, inflammation, anxiety and nausea. Contrary to the hallucinogenic ingredient of the plant, delta-9-tetrahydrocannabinol, cannabidiol does not seem to have a sedative effect, which can increase its popularity among users. The identification of cannabidiol in blood and urine has been widely described in the scientific literature for several years. Only few data after cannabis use has been reported regarding cannabidiol identification in alternative specimens, such as oral fluid, sweat, exhaled breath and hair. Cannabidiol capsules were purchased in the United States, from a grocery store and a green capsule containing 22 mg of cannabidiol was orally administered to a 59-year-old healthy man. Oral fluid was collected over 8 hours using the NeoSal™ device. Sweat was collected with PharmCheck™ sweat patch technology over 7 days. Exhaled breath was collected with the ExaBreath® DrugTrap device over 8 hours. Beard hair was collected 7 and 14 days after administration. Finally, urine specimens were collected over 48 hours in plastic tubes without preservative. Cannabidiol was only detected in oral fluid at 15 minutes, at 20 pg/mL. Increasing concentrations, up to 96 pg/patch of cannabidiol, were detected in the sweat patches. Cannabidiol was detected during 45 minutes in exhaled breath (Cmax 302 pg/filter at 30 minutes). Cannabidiol produced a very low but significant chromatographic signal in beard hair, with concentrations lower than 1 pg/mg. Finally, cannabidiol tested positive in urine after enzymatic hydrolysis with a Cmax at 70 ng/mL, after 6 hours.
Collapse
Affiliation(s)
- Alice Ameline
- Institut de médecine légale, 11 rue Humann, 67000 Strasbourg, France
| | | | - Pascal Kintz
- Institut de médecine légale, 11 rue Humann, 67000 Strasbourg, France
| |
Collapse
|
17
|
Abstract
Cannabis ranks among the most commonly used psychotropic drugs worldwide. In the context of the global movement toward more widespread legalisation, there is a growing need toward developing a better understanding of the physiological and pathological effects. We provide an overview of the current evidence on the effects of cannabinoids on the eye. Of the identified cannabinoids, Δ9-tetrahydrocannabinol is recognized to be the primary psychotropic compound, and cannabidiol is the predominant nonpsychoactive ingredient. Despite demonstrating ocular hypotensive and neuroprotective activity, the use of cannabinoids as a treatment for glaucoma is limited by a large number of potential systemic and ophthalmic side effects. Anterior segment effects of cannabinoids are complex, with preliminary evidence showing decreased corneal endothelial density in chronic cannabinoid users. Experiments in rodents, however, have shown potential promise for the treatment of ocular surface injury via antinociceptive and antiinflammatory effects. Electroretinography studies demonstrating adverse effects on photoreceptor, bipolar, and ganglion cell function suggest links between cannabis and neuroretinal dysfunction. Neuro-ophthalmic associations include ocular motility deficits and decrements in smooth pursuit and saccadic eye movements, although potential therapeutic effects for congenital and acquired nystagmus have been observed.
Collapse
|
18
|
McCartney MM, Thompson CJ, Klein LR, Ngo JH, Seibel JD, Fabia F, Simms LA, Borras E, Young BS, Lara J, Turnlund MW, Nguyen AP, Kenyon NJ, Davis CE. Breath carbonyl levels in a human population of seven hundred participants. J Breath Res 2020; 14:046005. [PMID: 32272460 DOI: 10.1088/1752-7163/ab8865] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Oxidative stress is associated with numerous health conditions and disorders, and aldehydes are known biomarkers of oxidative stress that can be non-invasively measured in exhaled human breath. Few studies report breath aldehyde levels in human populations, and none claim participant numbers in the hundreds or more. Further, the breath community must first define the existing aldehyde concentration variance in a normal population to understand when these levels are significantly perturbed by exogenous stressors or health conditions. In this study, we collected breath samples from 692 participants and quantified C4-C10 straight chain aldehyde levels. C9 aldehyde was the most abundant in breath, followed by C6. C4 and C5 appear to have bimodal distributions. Post hoc, we mined our dataset for other breath carbonyls captured by our assay, which involves elution of breath samples onto a solid phase extraction cartridge, derivatization and liquid chromatography-quadrupole time of flight mass spectrometry (LC-qTOF). We found a total of 21 additional derivatized compounds. Using self-reported demographic factors from our participants, we found no correlation between these breath carbonyls and age, gender, body mass index (BMI), ethnicity or smoking habit (tobacco and marijuana). This work was preceded by a small confounders study, which was intended to refine our breath collection procedure. We found that breath aldehyde levels can be affected by participants' using scented hygiene products such as lotions and mouthwashes, while collecting consecutive breath samples, rinsing the mouth with water, and filtering inspired air did not have an effect. Using these parameters to guide our sampling, subjects were instructed to avoid the prior conditions to provide a breath sample for our study.
Collapse
Affiliation(s)
- Mitchell M McCartney
- Mechanical and Aerospace Engineering, University of California, Davis, Davis, CA, United States of America
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Hubbard JA, Smith BE, Sobolesky PM, Kim S, Hoffman MA, Stone J, Huestis MA, Grelotti DJ, Grant I, Marcotte TD, Fitzgerald RL. Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. ACTA ACUST UNITED AC 2020; 58:673-681. [DOI: 10.1515/cclm-2019-0600] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 08/21/2019] [Indexed: 11/15/2022]
Abstract
AbstractBackgroundThe widespread availability of cannabis raises concerns regarding its effect on driving performance and operation of complex equipment. Currently, there are no established safe driving limits regarding ∆9-tetrahydrocannabinol (THC) concentrations in blood or breath. Daily cannabis users build up a large body burden of THC with residual excretion for days or weeks after the start of abstinence. Therefore, it is critical to have a sensitive and specific analytical assay that quantifies THC, the main psychoactive component of cannabis, and multiple metabolites to improve interpretation of cannabinoids in blood; some analytes may indicate recent use.MethodsA liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed to quantify THC, cannabinol (CBN), cannabidiol (CBD), 11-hydroxy-THC (11-OH-THC), (±)-11-nor-9-carboxy-Δ9-THC (THCCOOH), (+)-11-nor-Δ9-THC-9-carboxylic acid glucuronide (THCCOOH-gluc), cannabigerol (CBG), and tetrahydrocannabivarin (THCV) in whole blood (WB). WB samples were prepared by solid-phase extraction (SPE) and quantified by LC-MS/MS. A rapid and simple method involving methanol elution of THC in breath collected in SensAbues® devices was optimized.ResultsLower limits of quantification ranged from 0.5 to 2 μg/L in WB. An LLOQ of 80 pg/pad was achieved for THC concentrations in breath. Calibration curves were linear (R2>0.995) with calibrator concentrations within ±15% of their target and quality control (QC) bias and imprecision ≤15%. No major matrix effects or drug interferences were observed.ConclusionsThe methods were robust and adequately quantified cannabinoids in biological blood and breath samples. These methods will be used to identify cannabinoid concentrations in an upcoming study of the effects of cannabis on driving.
Collapse
Affiliation(s)
| | | | - Philip M. Sobolesky
- Department of Pathology and Laboratory Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA
| | - Sollip Kim
- Department of Laboratory Medicine, Inje University Ilsan Paik Hospital, Ilsan Seo-gu, Goyang, Republic of Korea
| | - Melissa A. Hoffman
- Department of Pathology, University of California, San Diego, CA 92121, USA
| | - Judith Stone
- University of California, San Francisco Medical Center, Laboratory Medicine, Parnassus Chemistry, San Francisco, CA, USA
| | - Marilyn A. Huestis
- The Lambert Center for the Study of Medicinal Cannabis and Hemp, Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA
| | - David J. Grelotti
- Department of Psychiatry, University of California, San Diego, CA, USA
| | - Igor Grant
- Department of Psychiatry, University of California, San Diego, CA, USA
| | | | | |
Collapse
|
20
|
Klimuntowski M, Alam MM, Singh G, Howlader MMR. Electrochemical Sensing of Cannabinoids in Biofluids: A Noninvasive Tool for Drug Detection. ACS Sens 2020; 5:620-636. [PMID: 32102542 DOI: 10.1021/acssensors.9b02390] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Cannabinoid sensing in biofluids provides great insight into the effects of medicinal cannabis on the body. The prevalence of cannabis for pain management and illicit drug use necessitates knowledge translation in cannabinoids. In this Review, we provide an overview of the current detection methods of cannabinoids in bodily fluids emphasizing electrochemical sensing. First, we introduce cannabinoids and discuss the structure and metabolism of Δ9-THC and its metabolites in relation to blood, urine, saliva, sweat, and breath. Next, we briefly discuss lab based techniques for cannabinoids in biofluids. While these techniques are highly sensitive and specific, roadside safety requires a quick, portable, and cost-effective sensing method. These needs motivated a comprehensive review of advantages, disadvantages, and future directions for electrochemical sensing of cannabinoids. The literature shows the lowest limit of detection to be 3.3 pg of Δ9-THC/mL using electrochemical immunosensors, while electrodes fabricated with low cost methods such as screen-printing and carbon paste can detect as little as 25 and 1.26 ng of Δ9-THC/mL, respectively. Future research will include nanomaterial modified working electrodes, for simultaneous sensing of multiple cannabinoids. Additionally, there should be an emphasis on selectivity for cannabinoids in the presence of interfering compounds. Sensors should be fully integrated on biocompatible substrates with control electronics and intelligent components for wearable diagnostics. We hope this Review will prove to be the seminal work in the electrochemical sensing of cannabinoids.
Collapse
Affiliation(s)
- Martin Klimuntowski
- Department of Electrical and Computer Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada
| | - Maksud M. Alam
- Department of Electrical and Computer Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada
| | - Gurmit Singh
- Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8, Canada
| | - Matiar M. R. Howlader
- Department of Electrical and Computer Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada
| |
Collapse
|
21
|
Olla P, Ishraque MT, Bartol S. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis Cannabinoid Res 2020; 5:99-104. [PMID: 32322681 DOI: 10.1089/can.2018.0070] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The legalization of cannabis in Canada brings novel challenges across various fronts, such as policy development, law enforcement, and public health and safety. It is imperative to improve our understanding of the mechanisms and trends surrounding cannabis use to develop efficacious methods of tackling these challenges. Materials and Methods: Patients' breath collection was achieved using the ExaBreath device from SensAbues. THC measurements in plasma and breath samples were processed and analyzed using LC-MS/MS. Discussion: We conducted a pragmatic clinical trial on 23 medical cannabis patients, wherein we collected breath and plasma samples intermittently for 4 hours after cannabis consumption. The research participants consumed between 1 and 2 g of cannabis by either vaping, cannabis cigarette, or concentrated wax (dabs) for 10 min. We used standardized laboratory analytical techniques using liquid chromatography-tandem mass spectrometry to analyze both the breath and plasma sample. To analyze the data and find patterns, we developed models using artificial neural network analysis. Conclusion: Our findings show that tetrahydrocannabinol (THC) breath concentrations peaked in 0.5 hours and reached baseline levels after 2 hours in all the patients. We found an inverse correlation between individuals' body mass index and their peak breath concentrations, and an inverse relationship between age and peak breath concentrations. Male participants had higher peak breath and plasma concentrations than female participants. Our research provides new insight into the correlations between breath and plasma THC concentrations in medical cannabis patients.
Collapse
Affiliation(s)
- Phillip Olla
- School of Computer Science, Faculty of Science, University of Windsor, Windsor, Canada
| | - Mohd Tazim Ishraque
- School of Computer Science, Faculty of Science, University of Windsor, Windsor, Canada
| | - Stephen Bartol
- School of Medicine, Wayne State University, Detroit, Michigan
| |
Collapse
|
22
|
Thevis M, Walpurgis K, Thomas A. Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions. Anal Chem 2019; 92:506-523. [DOI: 10.1021/acs.analchem.9b04639] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, Cologne 50933, Germany
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne 50933, Germany
| | - Katja Walpurgis
- Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, Cologne 50933, Germany
| | - Andreas Thomas
- Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, Cologne 50933, Germany
| |
Collapse
|
23
|
Lynch KL, Luo YR, Hooshfar S, Yun C. Correlation of Breath and Blood Δ9-Tetrahydrocannabinol Concentrations and Release Kinetics Following Controlled Administration of Smoked Cannabis. Clin Chem 2019; 65:1171-1179. [DOI: 10.1373/clinchem.2019.304501] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 06/18/2019] [Indexed: 11/06/2022]
Abstract
Abstract
BACKGROUND
Cannabis use results in impaired driving and an increased risk of motor vehicle crashes. Cannabinoid concentrations in blood and other matrices can remain high long after use, prohibiting the differentiation between acute and chronic exposure. Exhaled breath has been proposed as an alternative matrix in which concentrations may more closely correspond to the window of impairment; however, efficient capture and analytically sensitive detection methods are required for measurement.
METHODS
Timed blood and breath samples were collected from 20 volunteers before and after controlled administration of smoked cannabis. Cannabinoid concentrations were measured using LC-MS/MS to determine release kinetics and correlation between the 2 matrices.
RESULTS
Δ9-Tetrahydrocannabinol (THC) was detected in exhaled breath for all individuals at baseline through 3 h after cannabis use. THC concentrations in breath were highest at the 15-min timepoint (median = 17.8 pg/L) and declined to <5% of this concentration in all participants 3 h after smoking. The decay curve kinetics observed for blood and breath were highly correlated within individuals and across the population.
CONCLUSIONS
THC can be reliably detected throughout the presumed 3-h impairment window following controlled administration of smoked cannabis. The findings support breath THC concentrations as representing a physiological process and are correlated to blood concentrations, albeit with a shorter window of detection.
Collapse
Affiliation(s)
- Kara L Lynch
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
| | - Y Ruben Luo
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
| | - Shirin Hooshfar
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
| | - Cassandra Yun
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
| |
Collapse
|
24
|
Pourkarim F, Shayanfar A, Khoubnasabjafari M, Akbarzadeh F, Sajedi-Amin S, Jouyban-Gharamaleki V, Jouyban A. Determination of Verapamil in Exhaled Breath Condensate by Using Microextraction and Liquid Chromatography. CURR PHARM ANAL 2019. [DOI: 10.2174/1573412914666180717125434] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:Developing a simple analysis method for quantification of drug concentration is one of the essential issues in pharmacokinetic and therapeutic drug monitoring studies.Objective:A fast and reliable dispersive liquid-liquid microextraction procedure was employed for preconcentration of verapamil in exhaled breath condensate (EBC) samples and this was followed by the determination with high-performance liquid chromatography-ultraviolet detection.Methods:A reverse-phase high-performance liquid chromatography (RP-HPLC) combined with a dispersive liquid-liquid microextraction method (DLLME) was applied for quantification of verapamil in the EBC samples. The developed method was validated according to FDA guidelines.Results:Under the optimum conditions, the method provided a linear range between 0.07 and 0.8 µg.mL-1 with a coefficient of determination of 0.998. The intra- and inter-day relative standard deviation and relative error values of the method were below 15%, which indicated good precision and accuracy. The proposed method was successfully applied for the analysis of verapamil in two real samples with concentrations of 0.07 and 0.09 µg.mL-1.Conclusion:The established HPLC-UV-DLLME method could be applied for the analysis of verapamil in human EBC samples.
Collapse
Affiliation(s)
- Fariba Pourkarim
- Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ali Shayanfar
- Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran
| | - Maryam Khoubnasabjafari
- Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fariborz Akbarzadeh
- Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sanaz Sajedi-Amin
- Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Vahid Jouyban-Gharamaleki
- Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Abolghasem Jouyban
- Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
25
|
Beck O, Ullah S, Kronstrand R. First evaluation of the possibility of testing for drugged driving using exhaled breath sampling. TRAFFIC INJURY PREVENTION 2019; 20:238-243. [PMID: 31039047 DOI: 10.1080/15389588.2019.1584397] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 02/12/2019] [Accepted: 02/12/2019] [Indexed: 06/09/2023]
Abstract
Objective: Driving under the influence of psychoactive drugs causes an increased risk for accidents. In combating this, sobriety tests at the roadside are common practice in most countries. Sampling of blood and urine for forensic investigation cannot be done at the roadside and poses practical problems associated with costs and time. An alternative specimen for roadside testing is therefore warranted and the aerosol particles in exhaled breath are one such alternative. Methods: The present study investigated how the exhaled breath sample compared with the routine legal investigations of blood and urine collected from suspects of drugged driving at 2 locations in Sweden. Exhaled breath was collected using a simple filter collection device and analyzed with state-of-the-art mass spectrometry technique. Results: The total number of cases used for this investigation was 67. In 54 of these cases (81%) the results regarding a positive or negative drug test result agreed and in 13 they disagreed. Out of these, the report from the forensic investigation of blood/urine was negative in 21 cases. In 6 of these, analytical findings were made in exhaled breath and these cases were dominated by the detection of amphetamine. In 7 cases a positive drug test from the forensic investigation was not observed in the breath sample and these cases were dominated by detection of tetrahydrocannabinol in blood. In total, 45 samples were positive with breath testing and the number of positives with established forensic methods was 46. Conclusion: The promising results from this study provide support to exhaled breath as a viable specimen for testing of drugged driving. The rapid, easy, and convenient sampling procedure offers the possibility to collect a drug test specimen at the roadside. The analytical investigation must be done in a laboratory at present because of the need for a highly sensitive instrument, which is already in use in forensic laboratories. The analytical work is not more challenging than for blood or oral fluid and should not cause an increase in cost. However, more studies need to be done before exhaled breath drug testing can be applied routinely for drugged driving investigation.
Collapse
Affiliation(s)
- Olof Beck
- a Department of Laboratory Medicine, Division of Clinical Pharmacology , Karolinska Institutet , Stockholm , Sweden
| | - Shahid Ullah
- a Department of Laboratory Medicine, Division of Clinical Pharmacology , Karolinska Institutet , Stockholm , Sweden
| | - Robert Kronstrand
- b Department of Forensic Genetics and Forensic Toxicology , National Board of Forensic Medicine
- c Linköping University , Division of Drug Research , Linköping , Sweden
| |
Collapse
|
26
|
Garzinsky AM, Walpurgis K, Krug O, Thevis M. Does oral fluid contribute to exhaled breath samples collected by means of an electret membrane? Drug Test Anal 2019; 11:1764-1770. [PMID: 30927335 PMCID: PMC6973055 DOI: 10.1002/dta.2597] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 03/22/2019] [Accepted: 03/22/2019] [Indexed: 12/11/2022]
Abstract
To date, blood (and serum) as well as urine samples are the most commonly collected specimens for routine doping controls, which allow for the analytical coverage of an extensive set of target analytes relevant to sports drug testing programs. In the course of studies to identify potential alternative matrices to complement current testing approaches, exhaled breath (EB) has been found to offer advantageous properties especially with regard to the sample collection procedure, which is less invasive, less intrusive, and less time‐consuming when compared to conventional blood and urine testing. A yet unaddressed question has been the potential contribution of oral fluid (OF) to EB samples. The current investigation focused on characterizing an electret membrane‐based EB collection device concerning a potential introduction of OF during the sampling procedure. For that purpose, EB and OF samples collected under varying conditions from a total of 14 healthy volunteers were tested for the presence of abundant salivary proteins using bottom‐up proteomics approaches such as SDS‐PAGE followed by tryptic digestion and chromatographic‐mass spectrometric analysis. The trapping baffles integrated into the mouthpiece of the EB collection device were found to effectively retain OF introduced into the unit during sample collection as no saliva breakthrough was detectable using the established analytical approach targeting predominantly the highly abundant salivary α‐amylase. Since α‐amylase was found unaffected by storage, smoking, food intake, and exercise, it appears to be a useful marker to reveal possible OF contaminations of EB collection devices.
Collapse
Affiliation(s)
- Ann-Marie Garzinsky
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany
| | - Katja Walpurgis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany
| | - Oliver Krug
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany.,European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany.,European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany
| |
Collapse
|
27
|
Luo YR, Yun C, Lynch KL. Quantitation of Cannabinoids in Breath Samples Using a Novel Derivatization LC–MS/MS Assay with Ultra-High Sensitivity. J Anal Toxicol 2019; 43:331-339. [DOI: 10.1093/jat/bkz023] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Revised: 01/10/2019] [Accepted: 02/27/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
As the legalization of medical and recreational marijuana use expands, measurement of tetrahydrocannabinol (THC) in human breath has become an area of interest. The presence and concentration of cannabinoids in breath have been shown to correlate with recent marijuana use and may be correlated with impairment. Given the low concentration of THC in human breath, sensitive analytical methods are required to further evaluate its utility and window of detection. This paper describes a novel derivatization method based on an azo coupling reaction that significantly increases the ionization efficiency of cannabinoids for LC–MS/MS analysis. This derivatization reaction allows for a direct derivatization reaction with neat samples and does not require further sample clean-up after derivatization, thus facilitating an easy and rapid “derivatize & shoot” sample preparation. The derivatization assay allowed for limits of quantitation (LOQ’s) in the sub-pg/mL to pg/mL range for the five cannabinoids in breath samples, i.e., only 5~50 femtograms of an analyte was required for quantitation in a single analysis. This ultrahigh sensitivity allowed for the quantitation of cannabinoids in all breath samples collected within 3 hours of smoking cannabis (n = 180). A linear correlation between THC and cannabinol (CBN) in human breath was observed, supporting the hypothesis that CBN is converted from THC during the combustion of cannabis. The derivatization method was also applied to the analysis of cannabinoids in whole blood samples, achieving LOQ’s at ten-pg/mL to sub-ng/mL level. This azo coupling-based derivatization approach provided the needed analytical sensitivity for the analysis of THC in human breath samples using LC–MS/MS and could be a valuable tool for the analysis of other aromatic compounds in the future.
Collapse
Affiliation(s)
- Yiqi Ruben Luo
- Department of Laboratory Medicine, University of California San Francisco, and Zuckerberg San Francisco General Hospital, San Francisco, CA, USA
| | - Cassandra Yun
- Department of Laboratory Medicine, University of California San Francisco, and Zuckerberg San Francisco General Hospital, San Francisco, CA, USA
| | - Kara L Lynch
- Department of Laboratory Medicine, University of California San Francisco, and Zuckerberg San Francisco General Hospital, San Francisco, CA, USA
| |
Collapse
|
28
|
Seferaj S, Ullah S, Tinglev Å, Carlsson S, Winberg J, Stambeck P, Beck O. Evaluation of a new simple collection device for sampling of microparticles in exhaled breath. J Breath Res 2018; 12:036005. [PMID: 29440627 DOI: 10.1088/1752-7163/aaaf24] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The microparticle fraction of exhaled breath is of interest for developing clinical biomarkers. Exhaled particles may contain non-volatile components from all parts of the airway system, formed during normal breathing. This study aimed to evaluate a new, simple sampling device, based on impaction, for collecting microparticles from exhaled breath. Performance of the new device was compared with that of the existing SensAbues membrane filter device. The analytical work used liquid chromatography-tandem mass spectrometry methods. The new device collected three subsamples and these were separately analysed from eight individuals. No difference was observed between the centre position (0.91 ng/sample) and the side positions (1.01 ng/sample) using major phosphatidylcholine (PC) 16:0/16:0 as the analyte. Exhaled breath was collected from eight patients on methadone maintenance treatment. The intra-individual variability in measured methadone concentration between the three collectors was 8.7%. In another experiment using patients on methadone maintenance treatment, the sampling efficiency was compared with an established filter device. Compared to the existing device, the efficiency of the new device was 121% greater for methadone and 1450% greater for DPPC. The data from lipid analysis also indicated that a larger fraction of the collected material was from the distal parts. Finally, a study using an optical particle counter indicated that the device preferentially collects the larger particle fraction. In conclusion, this study demonstrates the usefulness of the new device for collecting non-volatile components from exhaled breath. The performance of the device was superior to the filter device in several aspects.
Collapse
Affiliation(s)
- Sabina Seferaj
- Karolinska University Laboratory, Department of Clinical Pharmacology, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
29
|
Ullah S, Sandqvist S, Beck O. A liquid chromatography and tandem mass spectrometry method to determine 28 non-volatile drugs of abuse in exhaled breath. J Pharm Biomed Anal 2017; 148:251-258. [PMID: 29059614 DOI: 10.1016/j.jpba.2017.10.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Revised: 10/06/2017] [Accepted: 10/09/2017] [Indexed: 01/10/2023]
Abstract
Exhaled breath carries aerosol micro-particles containing nonvolatile organic substances. Recently, the analysis of drugs of abuse (DOA) have become of interest in exhaled breath particles (EBP). In this study, a liquid chromatography - tandem mass spectrometry (LC-MS/MS) method was developed and validated to analyze 28 DOA in 30L of EBP collected on a permeable polymer filter. After extraction, the chromatographic separation was achieved on a UPLC BEH phenyl column using a mobile phase consisting of methanol and water both containing 4mmol/L ammonium formate and 0.05% ammonia. The column temperature was set at 50°C and mobile phase flow rate 0.5mL/min in gradient mode with a total run time of 5min. The mass spectrometer was operated in positive electrospray ionization and selected reaction monitoring mode. Acquired limits of quantification were in the range of 1-66pg/filter for all substances except DM-tramadol. Excellent linearity over the concentration range from LLOQs - 15ng/filter with r2 values >0.99 and satisfactory recoveries (70-116% at 100pg/filter) were achieved. During method application a total 26 samples were analyzed of which 24 were found to be positive for 13 analytes. The highest amount was found for methadone (56ng/filter) and the lowest amount was found for the methadone metabolite EDDP (2pg/filter) in two different samples.
Collapse
Affiliation(s)
- Shahid Ullah
- Department of Clinical Pharmacology, Karolinska University Hospital Laboratory and Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
| | - Sören Sandqvist
- Department of Clinical Pharmacology, Karolinska University Hospital Laboratory and Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Olof Beck
- Department of Clinical Pharmacology, Karolinska University Hospital Laboratory and Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
30
|
|
31
|
Trefz P, Kamysek S, Fuchs P, Sukul P, Schubert JK, Miekisch W. Drug detection in breath: non-invasive assessment of illicit or pharmaceutical drugs. J Breath Res 2017; 11:024001. [DOI: 10.1088/1752-7163/aa61bf] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
32
|
Kintz P, Jamey C, Ameline A, Richeval C, Raul JS. Characterization of metizolam, a designer benzodiazepine, in alternative biological specimens. TOXICOLOGIE ANALYTIQUE ET CLINIQUE 2017. [DOI: 10.1016/j.toxac.2016.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Kintz P, Mura P, Jamey C, Raul JS. Detection of ∆9-tetrahydrocannabinol in exhaled breath after cannabis smoking and comparison with oral fluid. Forensic Toxicol 2016. [DOI: 10.1007/s11419-016-0333-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|